Wedemeyer, H. Et Al. 2013. 96 weeks of pegylated Interferon alpha 2a plustenofovir or placebo for the treatment of hepatitis delta the HIDIT 2 study. AASLD 2013 .

Wedemeyer, H., YURTAYDIN, S. C., Ernst, S., Caruntu, F., Curescu, M. G., YALÇIN, K., ... AKARCA, U. S.(2013). 96 weeks of pegylated Interferon alpha 2a plustenofovir or placebo for the treatment of hepatitis delta the HIDIT 2 study . AASLD 2013

Wedemeyer, ONUR Et Al. "96 weeks of pegylated Interferon alpha 2a plustenofovir or placebo for the treatment of hepatitis delta the HIDIT 2 study," AASLD 2013, 2013

Wedemeyer, ONUR Et Al. "96 weeks of pegylated Interferon alpha 2a plustenofovir or placebo for the treatment of hepatitis delta the HIDIT 2 study." AASLD 2013 , 2013

Wedemeyer, H. Et Al. (2013) . "96 weeks of pegylated Interferon alpha 2a plustenofovir or placebo for the treatment of hepatitis delta the HIDIT 2 study." AASLD 2013 .

@conferencepaper{conferencepaper, author={ONUR KESKİN Et Al. }, title={96 weeks of pegylated Interferon alpha 2a plustenofovir or placebo for the treatment of hepatitis delta the HIDIT 2 study}, congress name={AASLD 2013}, city={}, country={}, year={2013}}